Key Developments: Prima BioMed Ltd (PBMD.OQ)
2.20USD
4:00pm EDT
$-0.28 (-11.29%)
$2.48
$2.45
$2.45
$2.00
14,074
1,852
$6.96
$2.00
Latest Key Developments (Source: Significant Developments)
Prima Biomed Ltd Awarded Japanese Patent for CVAC
Prima Biomed Ltd announced that it has been granted a patent from the Japanese Patent Office that protects methods used in the manufacture of CVac. The method of use claims secured in patent number 5192020 entitled “Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen” provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1. Full Article
Prima Biomed Ltd Commences "CANVAS" Clinical Trial In Europe
Prima Biomed Ltd announced that it has commenced recruitment of patients into the CANVAS (CANcer VAccine Study) trial in Europe. Prima has authorized several centers in Ukraine to start enrolling patients. CANVAS is a phase 2/3 study of CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy. Prima has obtained the requisite ethics and regulatory approvals in multiple European countries, including Belarus, Belgium, Bulgaria, Germany, Lithuania, Latvia, Poland and Ukraine. The Company anticipates that the majority of CANVAS patients will be enrolled in Europe. The trial is currently open for recruitment at a number of centers in the United States and Australia. Full Article
Prima BioMed Limited Not To Pay H1 2012/2013 Dividend
Prima BioMed Limited announced that no dividend was declared or paid for the first half of fiscal 2012/2013. Full Article
Prima Biomed Ltd Releases Interim Immune Monitoring Data From CVac Clinical Trial
Prima Biomed Ltd released interim immune monitoring data from its ongoing CAN-003 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy. The interim data demonstrate the positive effects of CVac treatment on the immune system. The Company has completed intracellular cytokine staining ("ICS") analysis of seven patients from the CAN-003 trial -- five patients from the CVac group and two patients from the control group, who did not receive any cancer treatment during the study. As compared to the control group, the CVac patients demonstrated much higher T cell activity throughout the testing period. ICS testing also indicates that the T cell response is specific to mucin 1, the antigen marker present on most ovarian cancer cells. Full Article
Prima Biomed Ltd Announces Change Of Chief Financial Officer
Prima Biomed Ltd announced that Mr. Marc Voigt, the Company's current Chief Business Officer, will assume the Chief Financial Officer role effective November 16, 2012. Full Article
Prima Biomed Ltd Announces Positive Interim Data From CAN-003 Trial of CVac for Ovarian Cancer
Prima Biomed Ltd announced positive trends in the interim data from the CAN-003 phase 2 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy. Interim progression free survival data show a favourable trend toward patients receiving CVac staying in remission longer than those in the observational standard of care (OSC) group. Combining overall data of first and second remission, the median progression free survival time (as of the date of data cut-off) is 421 days for non-randomized CVac, 365 days for CVac, and 321 days for OSC. The first seven patients on the study were not randomized and all seven were assigned to receive CVac in accordance with the trial design. Safety data to date indicate that CVac is very well tolerated as compared to observational standard of care (OSC). Preliminary intracellular cytokine staining (ICS) data in three CVac treated patients have shown a potent cytotoxic T cell response specific to mucin 1, while untreated patients did not show the same immune response. In the near term, upon completion of the analysis, the Company will release ICS data from a cohort of seven patients that have been followed for an extended period of time. Over the next year, Prima will have ICS data on all patients enrolled on the CAN-003 trial. Full Article
Prima Biomed Ltd Not To Pay FY 2011/2012 Final Dividend
Prima BioMed Limited announced that no final dividend was declared or paid for the year ended June 30, 2012. Full Article
Prima BioMed Limited to List on Frankfurt Stock Exchange
Prima BioMed Limited announced that it is to list its American depository receipts (ADRs) on the Entry Standard of the Frankfurt Stock Exchange as of June 5, 2012. Full Article
Prima BioMed Limited To Keep ASX Listing-DJ
Dow Jones reported that Prima BioMed Limited has no immediate plans to delist from the Australian stock exchange (ASX), despite recently appointing a new Chief Executive who will be based in San Francisco, Chairwoman Lucy Turnbull said earlier this week. Prima is also listed on the Nasdaq, with its securities beginning trading only last month. Full Article
Prima BioMed Limited Announces Board Changes
Prima BioMed Limited announced that Company's Chief Executive Officer, Martin Rogers will step down effective August 31, 2012. Mr. Rogers will remain on Prima's board as a non-executive director from September 1, 2012. Matthew Lehman, the Company's Chief Operating Officer, will assume the CEO role effective September 1, 2012. Mr. Lehman will join the Prima board of directors effective May 24, 2012. Mr. Lehman will be the Acting CEO during the period of Mr. Rogers' nuptial leave until the end of July 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
